HDT

Administrators Report Roughly Half of Public School Students Began 2022-23 School Year Behind Grade Level in At Least One Academic Subject

Retrieved on: 
Thursday, February 9, 2023
National Center for Education Statistics, HDT, PD, SDT, U.S. Department of Education, Office of Inspector General, Mathematics, United States Secretary of Education, Education sciences, Quarantine, Research, School, Privacy Office of the U.S. Department of Homeland Security, Parent, Student, Policy, Curriculum, IES, NCES, Learning, Prevalence, COVID-19, SPT, Tutoring, Management, Education

WASHINGTON, Feb. 9, 2023 /PRNewswire/ -- Public school leaders estimated that about half—49 percent—of their students began the 2022-23 year behind grade level in at least one academic subject, according to data released today by the National Center for Education Statistics (NCES), the statistical center within the U.S. Department of Education's Institute of Education Sciences (IES). Almost all public schools with students behind grade level in at least one academic subject reported that at least some students were behind grade level in English or mathematics. 

Key Points: 
  • Almost all public schools with students behind grade level in at least one academic subject reported that at least some students were behind grade level in English or mathematics.
  • "Both this school year and last school year, public school leaders estimated that about half of their students began the school year behind grade level in at least one academic subject.
  • In addition to the strategies mentioned above, most public schools provide some type of tutoring to their students (83 percent).
  • Entering the 2022-23 school year, public schools estimated that, on average, 49 percent of their students began the year behind grade level in at least one academic subject.

Ashvattha Therapeutics Announces First Patient Enrolled in a Phase 1 Study of [18F]OP-801 for Use as Imaging Agent

Retrieved on: 
Monday, February 6, 2023
Amyotrophic lateral sclerosis, Disease, Stanford University School of Medicine, Safety, HD, Trial of the century, Neuroinflammation, Pharmacokinetics, Microglia, CT, Neurodegeneration, Patient, HDT, Clinical trial, ALS, Precision medicine, Doctor of Philosophy, Brain, Therapy, Inflammation, Medical imaging

REDWOOD CITY, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (“Ashvattha”), a clinical-stage company developing novel nanomedicines called hydroxyl dendrimer therapeutics (HDT), today announced that the first patient has been enrolled in a Phase 1/2 clinical study to evaluate the safety, pharmacokinetics and biodistribution of an intravenously administered dose of [18F]OP-801 in healthy volunteers and in patients with amyotrophic lateral sclerosis (ALS) (NCT05395624). [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.

Key Points: 
  • [18F]OP-801 is a hydroxyl dendrimer (HD) imaging agent that selectively targets reactive macrophages and microglia – key markers of neuroinflammation.
  • “The initiation of the clinical trial evaluating [18F]OP-801 as an imaging agent is a significant step to unlocking the potential of our proprietary HD technology for treatment of neurological diseases,” said Jeffrey Cleland, Ph.D., chairman, CEO and president of Ashvattha Therapeutics.
  • “With [18F]OP-801, we will be able to estimate HDT uptake in the diseased part of the brain prior to treating patients with the HDT.
  • The study will also measure the biodistribution and clearance of the HD imaging agent in both populations and evaluate the uptake of [18F]OP-801 in regions of neuroinflammation in ALS patients using PET/computed tomography (CT) scans.

Yescarta® Now Approved in Japan for Initial Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Retrieved on: 
Thursday, December 22, 2022
Oncology, Health, Hospitals, Genetics, Pharmaceutical, Biotechnology, HDT, Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, Standard of care, Daiichi Sankyo, ASCT, SOC, Multimedia, B-cell lymphoma, Non-Hodgkin lymphoma, CAR, Patient, MHLW, CD19, Standard, EFS, TSE, Pharma, Doctor of Philosophy, Pharmaceutical industry, Health, Axicabtagene ciloleucel

Yescarta should be used only in patients who have not received prior transfusion of CAR T-cells targeted at CD19 antigen.

Key Points: 
  • Yescarta should be used only in patients who have not received prior transfusion of CAR T-cells targeted at CD19 antigen.
  • Although approximately 60% of newly diagnosed LBCL patients will respond to the initial treatment with chemotherapy, 40% will relapse or will not respond and need second-line treatment.
  • Yescarta is now approved for the initial treatment of R/R LBCL patients in Japan.
  • Kite’s manufacturing facility in El Segundo, California, U.S., has been approved by Japanese regulatory authorities to commence manufacturing Yescarta for the Japan market in 2023.

Electric Coolant Pump Market Forecast to 2028: Integration of Innovative Features Creating Opportunities - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 21, 2022
Automotive Manufacturing, EV, Electric Vehicles, Manufacturing, Automotive, Government, Mahle GmbH, HDT, Little League World Series (Middle East-Africa Region), Continental AG, EV, Heat, Power, SUV, COVID-19, Royal commission, Application, EVS, City, LCV, European Commission, Continental, Sale, Renewable energy, Lithium, Rail transport

The "Electric Coolant Pump Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application, Power, Vehicle Type, Propulsion Type and Pump Type" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Electric Coolant Pump Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Application, Power, Vehicle Type, Propulsion Type and Pump Type" report has been added to ResearchAndMarkets.com's offering.
  • These investment plans are expected to impact the electric coolant pump market positively.
  • Thus, the growing demand for EVs is expected to bolster the demand for electric coolant pumps in North America.
  • Thus, the growing sale of LCVs, electric buses, and passenger cars in China is expected to propel the demand for electric coolant pumps.

BioAegis Therapeutics Highlights Recent Article on its Novel Host-Directed Protein, Plasma Gelsolin, for Inflammatory Diseases

Retrieved on: 
Monday, December 5, 2022
HDT, Kidney, Drive, Saipan, Inflammation, Telephone numbers in South Africa, Sepsis, Infection, Disease, Multiple sclerosis, IP, Plasma, BARDA, Therapy, Blood, Pharmaceutical industry

Companies are challenged with finding treatments for the countless autoimmune and inflammatory disorders that affect millions of people globally.

Key Points: 
  • Companies are challenged with finding treatments for the countless autoimmune and inflammatory disorders that affect millions of people globally.
  • The ravages of inflammatory disease are on the rise and drive considerable morbidity as well as stress on the healthcare system.
  • It holds over 40 patents issued for coverage of infection, inflammatory disease, renal failure, multiple sclerosis, and other neurologic diseases.
  • BioAegis will also have US biologics exclusivity and has recently filed new IP in areas of unmet need.

Angiocrine Bioscience Announces Poster Presentation of AB-205 Trial during the 64th Annual Meeting of the American Society of Hematology (ASH)

Retrieved on: 
Friday, December 9, 2022
ClinicalTrials.gov, Food, Collateral damage, MD, Endothelium, Hospital, Society, Patient, National Institutes of Health, AB-205, US Food Sovereignty Alliance, Lymphoma, Safety, HDT, Tissue, Regenerative medicine, Infection, SAN, ASH, Pharmaceutical industry, Angiocrine growth factors

"Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO.

Key Points: 
  • "Our investigators and Angiocrine are honored to be selected by ASH to present at its annual meeting this December," commented Paul Finnegan, MD, Angiocrine CEO.
  • "We look forward to Dr. Michael Scordo's presentation on the trial design of our AB-205 Phase 3 multi-center study (E-CELERATE)."
  • Angiocrine Bioscience, Inc. is a clinical-stage biopharmaceutical company developing Advanced Reparative Medicines consisting of engineered human endothelial cells (E-CEL cells).
  • Angiocrine utilizes its proprietary E-CEL Platform to create multiple versions of E-CEL cells to repair damaged tissues and organs and to treat serious medical conditions.

EQS-News: Polyvisions selects FRX Innovations’ Nofia® Technology for its line of FR PET Molded and Extruded Products

Retrieved on: 
Friday, November 11, 2022
Benchmark, EV, FR, PCR, GreenScreen for Safer Chemicals, UL, Electronics, Polymer, Medicine, Solution, Company, Plastic, Engineering, Hospital, CTI, EPA, News, TSX Venture Exchange, Environment, Global, TSX, Chroma key, Phrase, PET, Port of Antwerp, Legislation, Efficiency, Ernst & Young Entrepreneur of the Year Award, FSE, HDT, Port, Terminology, Flanders, Consumer, Textile, OTC, Membrane, Goal, Safety, FRX, Flanders Investment and Trade, TCO, 3D printing, Thermoplastic, Printed circuit board, PolyVision (company)

Nofias unique polymeric phosphorus-based chemistry helps make DuraPET more sustainable and technically superior for polyester medical and consumer electronics applications.

Key Points: 
  • Nofias unique polymeric phosphorus-based chemistry helps make DuraPET more sustainable and technically superior for polyester medical and consumer electronics applications.
  • Nofia Homopolymers and Copolymer Flame retardant additives have achieved the highest rating of Benchmark 3 in the well-recognized Green Screen Assessment.
  • We looked at a lot of non-halogenated FR additives, says Rick Wilson of PolyVisions, but none performed as well as Nofia Polyphosphonates in mechanicals and FR performance.
  • DuraPET 624 FR is a graft modified PET material that has a UL V0 listing for flame retardancy enabled by Nofia non-halogenated flame retardant additives.

HDT Bio Selected to Join BLUE KNIGHT™

Retrieved on: 
Monday, November 7, 2022
Biotechnology, Pharmaceutical, Medical Supplies, Oncology, General Health, Health, Infectious Diseases, Clinical Trials, The Blue Knight, RNA, Public health, National Cancer Institute, Therapy, RNA transfection, SaRNA, HDT, Administration, Human services, Johnson & Johnson, Biomedical Advanced Research and Development Authority, Unitary state, Military personnel, Vaccine, COVID-19, Office of Inspector General, U.S. Department of Health and Human Services, Incubator, Infection, View, U.S. Department of Defense Strategy for Operating in Cyberspace, Government, HHS, Immune system, Development, Technology, ASPR, Cancer, BARDA

We are grateful to JLABS and BARDA to be named a Blue Knight company , said HDT Bio CEO Steve Reed.

Key Points: 
  • We are grateful to JLABS and BARDA to be named a Blue Knight company , said HDT Bio CEO Steve Reed.
  • HDT Bio is focused on applying self-amplifying RNA (saRNA) with its proprietary LION delivery system to develop immunotherapies for infectious diseases and cancer.
  • HDT Bio also is collaborating with National Cancer Institute to develop saRNA vaccines to prevent and treat multiple cancers.
  • Through Blue Knight, HDT Bio will be a virtual company in JLABS , a global network of life science incubators.

Polyvisions Durapet PET Material Available in Flame Retardant Formulations for Medical and Consumer Electronics Applications

Retrieved on: 
Wednesday, November 2, 2022
Benchmark, Electronics, Goal, Consumer, PolyVision (company), PCR, Key, CTI, Polymer, PET, Medicine, HDT, FR, Membrane, GreenScreen for Safer Chemicals, Multimedia, Engineering, Plastic, UL, Solution, Printed circuit board, Thermoplastic

MANCHESTER, Pa., Nov. 2, 2022 /PRNewswire/ -- Polyvisions Inc. a premiere thermoplastic compounding solutions provider (a wholly owned subsidiary of Bemis Associates Inc.), announces DuraPET 624 FR™ and DuraPET PCR FR products with Nofia® brand of polyphosphonates flame retardants as additives for Medical and Consumer electronic housing and applications. Nofia is produced by FRX Polymers, Inc.

Key Points: 
  • Nofia Homopolymers and Copolymer Flame retardant additives have achieved the highest rating of Benchmark 3 in the well-recognized Green Screen Assessment.
  • In a related development, Washington State has included Polyvisions DuraPET 624FR based on Nofia Polyphosphonates in their list of alternatives to Halogenated FR compounds for Consumer electronics applications.
  • DuraPET 624 FR is a graft modified PET material that has a UL V0 listing for flame retardancy enabled by Nofia non-halogenated flame retardant additives.
  • This makes DuraPET 624 FR potentially ideal for applications such as medical instrumentation and consumer electronic housings.

Ashvattha Therapeutics Announces the Appointment of Steve Maricich, M.D., Ph.D. as Chief Medical Officer

Retrieved on: 
Thursday, October 20, 2022
DME, Disease, Therapy, Hospital, Growth, Organization, NIH, Baylor University, HDS, Inflammation, GI, Johns Hopkins University, Cancer, Precision medicine, University, Diabetic retinopathy, Industry, Neurology, CEO, Pediatrics, Case Western Reserve University, Nanomedicine, GLOBE, HDT, CMO, Brain, Doctor of Philosophy, Child, Hematology, Neuro, BioMarin Pharmaceutical, AMD, Pharmaceutical industry, Ashvattha, Ophthalmology

REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Ashvattha Therapeutics (Ashvattha), a clinical-stage company developing novel hydroxyl dendrimer therapeutics (HDTs), today announced that Steve Maricich, M.D., Ph.D., joined the company as chief medical officer.
  • We are thrilled to welcome Dr. Maricich to our senior management team, said Jeff Cleland, Ph.D., chairman and CEO of Ashvattha.
  • Dr. Maricich joins Ashvattha from Calibr and Scripps BioVentures, where he served as the chief medical officer.
  • Ashvattha Therapeutics is a clinical-stage biotech company developing novel hydroxyl dendrimer therapeutics (HDTs) targeting unmet medical needs in ophthalmology, neurology, inflammation and neuro-oncology.